SLC7A5

Large neutral amino acids transporter small subunit 1 · Q01650 · SLC7A5 on Sugi Atlas →

58,638 patent compounds predicted against SLC7A5, 35,751 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL42906	0.65	10/20
SCHEMBL42907	0.65	10/20
Propiolic Acid (SCHEMBL143598)	0.44	10/20
SCHEMBL44026	0.65	9/20
SCHEMBL44027	0.65	9/20
M-Fluorophenylalanine (SCHEMBL42948)	0.65	8/20
M-Fluorophenylalanine (SCHEMBL42949)	0.65	8/20
SCHEMBL159869	0.65	8/20
SCHEMBL159870	0.65	8/20
SCHEMBL43811	0.59	8/20
SCHEMBL43812	0.59	8/20
Seproxetine (SCHEMBL120303)	0.80	7/20
Norfluoxetine (SCHEMBL140929)	0.80	7/20
Levodopa (SCHEMBL170258)	0.69	7/20
SCHEMBL147042	0.67	7/20
SCHEMBL44155	0.59	7/20
SCHEMBL44156	0.59	7/20
Glutarate (SCHEMBL140225)	0.53	7/20
SCHEMBL144865	0.51	7/20
Sulfuric Acid (SCHEMBL143603)	0.49	7/20

Clinical trials — most relevant to SLC7A5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Kuvan on Melatonin Secretion	PHASE4	COMPLETED
L-arginine Treatment in Mild Hypertension	PHASE4	UNKNOWN
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia	PHASE1/PHASE2	RECRUITING
DAAOI-1 Treatment for Treatment-resistant Schizophrenia	PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Bioavailability of Paracetamol, Amoxicillin and Talinolol Before, Immediately and One Year After Gastric Bypass Operation	PHASE1	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
[18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy	nan	UNKNOWN
Protein Digestion and Amino Acid Absorption in the Aging Gastrointestinal Tract	nan	COMPLETED
Gene Expression in Inflammatory Bowel Disease	nan	ENROLLING_BY_INVITATION
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)	nan	UNKNOWN
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features	nan	UNKNOWN
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
Clinical Utility of Breath Tests in GI	nan	COMPLETED
Optimizing Protein Patterns for Skeletal Muscle Preservation and Sleep in the Medical Management of Parkinson Disease	nan	COMPLETED
The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome	nan	UNKNOWN
Zinc and Diabetes in Patients With Thalassemia: a Pilot Study	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
The Incorporation of Dietary Protein-Derived Amino Acids in Duodenal Epithelium	nan	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Fluorescence and Glioma Heterogeneity	nan	COMPLETED
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency	nan	NO_LONGER_AVAILABLE

Related proteins — ESM-2 sequence neighbours (a SLC7A5 binder may also engage these)

Protein	Name	Similarity
Q9Z127	—	1.000	Q9Z127 →
Q63016	—	1.000	Q63016 →
Q7YQK4	—	1.000	Q7YQK4 →
D3ZMM8	—	0.997	D3ZMM8 →
SLC7A11	Cystine/glutamate transporter	0.993	landscape →
Q5RAG7	—	0.992	Q5RAG7 →
Q8BGK6	—	0.992	Q8BGK6 →
Q92536	—	0.990	Q92536 →
Q9WTR6	—	0.990	Q9WTR6 →
Q9R0S5	—	0.989	Q9R0S5 →
Q9Z1K8	—	0.989	Q9Z1K8 →
Q9UM01	—	0.987	Q9UM01 →
A1L3M3	—	0.986	A1L3M3 →
Q28I80	—	0.986	Q28I80 →
Q3ZMH1	—	0.984	Q3ZMH1 →
Q9N1Q4	—	0.981	Q9N1Q4 →
Q9UHI5	—	0.981	Q9UHI5 →
Q5RAE3	—	0.981	Q5RAE3 →
Q9WVR6	—	0.980	Q9WVR6 →
A7MBD8	—	0.977	A7MBD8 →
Q49B93	—	0.977	Q49B93 →
Q8WY07	—	0.977	Q8WY07 →
P30823	—	0.977	P30823 →
Q1EHB4	—	0.976	Q1EHB4 →
Q59I64	—	0.974	Q59I64 →
SLC7A1	High affinity cationic amino acid transporter 1	0.974	landscape →
Q7T384	—	0.974	Q7T384 →
Q9QXW9	—	0.973	Q9QXW9 →
P70423	—	0.972	P70423 →
Q6DCE8	—	0.972	Q6DCE8 →